Key Points
- Director Michael Barber bought 15,175 shares of DENTSPLY SIRONA at an average price of $9.88, lifting his stake by 37.22% to 55,943 shares, according to an SEC filing.
- The stock was modestly higher, trading up 0.5% to $10.14, while still sitting below both its 50-day and 200-day moving averages.
- Analysts remain cautious overall: the average rating is “Hold” with a $13.55 target price, though opinions are mixed and recent earnings showed a small EPS miss despite stronger-than-expected revenue.
DENTSPLY SIRONA Inc. (NASDAQ:XRAY - Get Free Report) Director Brian Gladden acquired 9,985 shares of the stock in a transaction dated Monday, June 15th. The stock was acquired at an average price of $10.02 per share, for a total transaction of $100,049.70. Following the completion of the transaction, the director directly owned 61,849 shares of the company's stock, valued at approximately $619,726.98. This represents a 19.25% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.
DENTSPLY SIRONA Stock Performance
NASDAQ XRAY opened at $10.14 on Tuesday. The company has a quick ratio of 0.98, a current ratio of 1.53 and a debt-to-equity ratio of 1.52. DENTSPLY SIRONA Inc. has a twelve month low of $9.40 and a twelve month high of $17.09. The business has a 50-day moving average price of $10.95 and a 200-day moving average price of $11.71. The firm has a market cap of $2.03 billion, a price-to-earnings ratio of -3.22, a price-to-earnings-growth ratio of 1.20 and a beta of 0.89.
DENTSPLY SIRONA (NASDAQ:XRAY - Get Free Report) last issued its earnings results on Tuesday, May 5th. The medical instruments supplier reported $0.27 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.28 by ($0.01). DENTSPLY SIRONA had a negative net margin of 17.06% and a positive return on equity of 18.83%. The business had revenue of $880.00 million for the quarter, compared to the consensus estimate of $841.80 million. During the same period last year, the business posted $0.43 EPS. The firm's revenue for the quarter was up .1% compared to the same quarter last year. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. As a group, equities research analysts predict that DENTSPLY SIRONA Inc. will post 1.42 EPS for the current fiscal year.
Analyst Ratings Changes
XRAY has been the topic of several research analyst reports. Zacks Research raised shares of DENTSPLY SIRONA from a "strong sell" rating to a "hold" rating in a report on Monday, March 2nd. Bank of America upgraded shares of DENTSPLY SIRONA from a "neutral" rating to a "buy" rating and lifted their price target for the company from $13.00 to $17.00 in a report on Thursday, February 19th. Barclays decreased their price target on shares of DENTSPLY SIRONA from $12.00 to $9.00 and set an "underweight" rating on the stock in a research note on Thursday, June 4th. Robert W. Baird raised their price objective on DENTSPLY SIRONA from $12.00 to $14.00 and gave the company a "neutral" rating in a research report on Friday, February 27th. Finally, UBS Group reduced their target price on DENTSPLY SIRONA from $18.00 to $17.00 and set a "buy" rating on the stock in a report on Thursday, May 7th. Three research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and three have issued a Sell rating to the company. Based on data from MarketBeat.com, DENTSPLY SIRONA currently has an average rating of "Hold" and a consensus price target of $13.55.
Get Our Latest Report on XRAY
Institutional Investors Weigh In On DENTSPLY SIRONA
Several large investors have recently bought and sold shares of XRAY. Eurizon Capital SGR S.p.A. purchased a new stake in DENTSPLY SIRONA during the fourth quarter valued at $26,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new position in shares of DENTSPLY SIRONA in the 1st quarter worth $26,000. Huntington National Bank grew its stake in shares of DENTSPLY SIRONA by 292.9% in the 3rd quarter. Huntington National Bank now owns 2,786 shares of the medical instruments supplier's stock worth $35,000 after buying an additional 2,077 shares in the last quarter. Caitong International Asset Management Co. Ltd increased its holdings in shares of DENTSPLY SIRONA by 337.9% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 2,750 shares of the medical instruments supplier's stock worth $35,000 after buying an additional 2,122 shares during the last quarter. Finally, Farther Finance Advisors LLC raised its position in shares of DENTSPLY SIRONA by 119.1% during the 4th quarter. Farther Finance Advisors LLC now owns 3,773 shares of the medical instruments supplier's stock valued at $43,000 after buying an additional 2,051 shares in the last quarter. Institutional investors own 95.70% of the company's stock.
About DENTSPLY SIRONA
(
Get Free Report)
Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.
The company's product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
